The health system is partnering with pharmaceutical company Eisai to study the value of an algorithm, known as a Passive Digital Marker, on a set of de-identified data to identify individuals dealing with cognitive impairment, which may suggest early signs of dementia, according to an April 4 press release.
“As we continue to develop new treatments to prevent and slow the progression of Alzheimer’s and related dementias, early detection is becoming even more important,” said Glen Finney, MD, director of Geisinger’s Memory and Cognition Program. “Early and accurate diagnosis and treatment of these conditions can drastically improve outcomes and quality of life for both patients and caregivers.”
The AI technology aims to better understand the root causes of dementia and other neurological conditions, to aid in better treatments and early detection.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
